531681 AMERISE

Amerise Biosciences Share Price

 

 

Start SIP in AMERISE

Start SIP

Performance

  • Low
  • ₹1
  • High
  • ₹1
  • 52 Week Low
  • ₹1
  • 52 Week High
  • ₹1
  • Open Price₹1
  • Previous Close₹1
  • Volume300,645
  • 50 DMA₹0.66
  • 100 DMA₹0.66
  • 200 DMA₹0.71

Investment Returns

  • Over 1 Month + 11.11%
  • Over 3 Month + 7.69%
  • Over 6 Month + 1.45%
  • Over 1 Year -28.57%

Smart Investing Starts Here Start SIP with Amerise Biosciences for Steady Growth!

Invest Now

Amerise Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 70.9
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 5
  • P/B Ratio
  • 0.9
  • Average True Range
  • 0.05
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.03
  • RSI
  • 52.02
  • MFI
  • 72.02

Amerise Biosciences Financials

Amerise Biosciences Technicals

EMA & SMA

Current Price
₹0.70
-0.1 (-12.5%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹0.70
  • 50 Day
  • ₹0.66
  • 100 Day
  • ₹0.66
  • 200 Day
  • ₹0.71

Resistance and Support

0.73 Pivot Speed
  • R3 0.87
  • R2 0.83
  • R1 0.77
  • S1 0.67
  • S2 0.63
  • S3 0.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Amerise Biosciences has an operating revenue of Rs. 8.66 Cr. on a trailing 12-month basis. An annual revenue growth of 375% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 35 which is a POOR score indicating inconsistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 105 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Amerise Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-02 Quarterly Results
2025-11-05 Quarterly Results
2025-07-24 Quarterly Results
2025-05-19 Audited Results
2025-02-03 Quarterly Results & Others Inter-alia, to consider 1. Appointment of Mr. Kelash Bunkar as Director of the Company. 2. Resignation of Mr. Niraj Vaghela from directorship of the company. 3.Other business matters.

Amerise Biosciences F&O

Amerise Biosciences Shareholding Pattern

0%
72.01%
27.99%

Amerise Biosciences FAQs

Amerise Biosciences share price is ₹0 As on 11 February, 2026 | 23:15

The Market Cap of Amerise Biosciences is ₹4.6 Cr As on 11 February, 2026 | 23:15

The P/E ratio of Amerise Biosciences is 70.9 As on 11 February, 2026 | 23:15

The PB ratio of Amerise Biosciences is 0.9 As on 11 February, 2026 | 23:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23